Internal Reference Number: FOI_8886
Date Request Received: 04/09/2025 00:00:00
Date Request Replied To: 16/09/2025 00:00:00
This response was sent via: By Email
Request Summary: Biologics (Dermatology)
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: 鈥� Adalimumab - Humira 鈥� Adalimumab Biosimilar 鈥� Apremilast 鈥� Bimekizumab 鈥� Brodalumab 鈥� Certolizumab 鈥� Deucravacitinib 鈥� Dimethyl fumarate 鈥� Etanercept - Enbrel 鈥� Etanercept Biosimilar 鈥� Guselkumab 鈥� Infliximab - Remicade 鈥� Infliximab Biosimilar 鈥� Ixekizumab 鈥� Risankizumab 鈥� Secukinumab 鈥� Tildrakizumab 鈥� Ustekinumab - Stelara 鈥� Ustekinumab Biosimilar 鈥� Omalizumab 鈥� Spesolimab | |
| Answer To Question 1: Please see our response to all questions in the file attached. To accompany this answer to question 1 please also see the documents listed below:  13232 - FOI_8886 - Biologics Dermatology - FOR ISSUE.xlsx | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following: 鈥� Adalimumab - Humira 鈥� Adalimumab Biosimilar 鈥� Bimekizumab 鈥� Certolizumab 鈥� Infliximab - Remicade 鈥� Infliximab Biosimilar 鈥� Secukinumab 鈥� Ustekinumab - Stelara 鈥� Ustekinumab Biosimilar | |
| Answer To Question 2: Please see our response to all questions in the file attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
